Most Read Articles
Jenny Ng, 2 years ago

The WHO’s 2014 World Cancer Report predicts a crisis in cancer over the next 20 years, with a 75 percent surge in cases worldwide from 2008 and a projected economic cost totalling USD 1 trillion. 

one year ago
Maintenance rituximab (MR) after autologous stem cell transplantation (ASCT) may improve overall survival (OS) of patient with mantle cell lymphoma (MCL).
one year ago
An in vivo sensitivity testing confirmed that pimasertib, a selective allosteric MEK1/2 inhibitor, enhances gemcitabine efficacy in human pancreatic cancer cell lines by reducing the levels of ribonucleotide reductase subunit-1 (RRM1) protein.
one year ago
Cediranib has demonstrated significant efficacy when added to carboplatin and paclitaxel in the treatment of metastatic or recurrent cervical cancer.

Neoadjuvant Treatment of Early Breast Cancer

2 months ago
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jenny Ng, 2 years ago

The WHO’s 2014 World Cancer Report predicts a crisis in cancer over the next 20 years, with a 75 percent surge in cases worldwide from 2008 and a projected economic cost totalling USD 1 trillion. 

one year ago
Maintenance rituximab (MR) after autologous stem cell transplantation (ASCT) may improve overall survival (OS) of patient with mantle cell lymphoma (MCL).
one year ago
An in vivo sensitivity testing confirmed that pimasertib, a selective allosteric MEK1/2 inhibitor, enhances gemcitabine efficacy in human pancreatic cancer cell lines by reducing the levels of ribonucleotide reductase subunit-1 (RRM1) protein.
one year ago
Cediranib has demonstrated significant efficacy when added to carboplatin and paclitaxel in the treatment of metastatic or recurrent cervical cancer.